{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:48:45Z","timestamp":1765295325729,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RE 4782\/1-1"],"award-info":[{"award-number":["RE 4782\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.urolonc.2022.09.012","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T03:27:30Z","timestamp":1666063650000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III"],"prefix":"10.1016","volume":"41","author":[{"given":"M.J.","family":"Reike","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Ingersoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.C.M.","family":"Zuiverloon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Strandgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Todenh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Goebell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Schmitz-Dr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-7068","authenticated-orcid":false,"given":"P.C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.urolonc.2022.09.012_bib0001","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Guerin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"4682","key":"10.1016\/j.urolonc.2022.09.012_bib0002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Gu\u00e9rin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"issue":"2S","key":"10.1016\/j.urolonc.2022.09.012_bib0003","first-page":"S142","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"197","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.012_bib0004","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.012_bib0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.09.012_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2022.09.012_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100472","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.012_bib0008","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.urolonc.2022.09.012_bib0009","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00345-018-2257-z","article-title":"Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Bayne","year":"2018","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.012_bib0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JU.0000000000000296","article-title":"Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"202","author":"Anger","year":"2019","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.012_bib0011","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eururo.2020.06.032","article-title":"The EAU and AUA\/CUA\/SUFU guidelines on recurrent urinary tract infections: what is the difference?","volume":"78","author":"Naber","year":"2020","journal-title":"Eur Urol"},{"issue":"13","key":"10.1016\/j.urolonc.2022.09.012_bib0012","article-title":"Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection","volume":"4","author":"Zychlinsky Scharff","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.012_bib0013","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00256185","article-title":"Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine","volume":"3","author":"Okajima","year":"1975","journal-title":"Urol Res"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.012_bib0014","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ajpath.2013.01.018","article-title":"Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor","volume":"182","author":"Hsu","year":"2013","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148851","article-title":"Conditional expression of the androgen receptor increases susceptibility of bladder cancer in mice","volume":"11","author":"Johnson","year":"2016","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.urolonc.2022.09.012_bib0016","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.18632\/oncotarget.2851","article-title":"Androgen deprivation therapy prevents bladder cancer recurrence","volume":"5","author":"Izumi","year":"2014","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.urolonc.2022.09.012_bib0017","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/j.1464-410X.2011.10706.x","article-title":"Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder","volume":"109","author":"Miyamoto","year":"2012","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.012_bib0018","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1464-410X.2009.09137.x","article-title":"The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder","volume":"106","author":"Boorjian","year":"2010","journal-title":"BJU Int"},{"issue":"0","key":"10.1016\/j.urolonc.2022.09.012_bib0019","article-title":"Androgen conspires with the CD8+T cell exhaustion program and contributes to sex bias in cancer","volume":"0","author":"Kwon","year":"2022","journal-title":"Science Immunology"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0020","doi-asserted-by":"crossref","unstructured":"Rousseau M, O'Brien CJO, Antequera E, Zdimerova H, Cansever D, Canton T, et al. Identification of sex differences in tumor-specific T cell infiltration in bladder tumor-bearing mice treated with BCG immunotherapy. In press, Bladder Cancer, available on BioRxiv. 2020:2020.06.19.161554.","DOI":"10.1101\/2020.06.19.161554"},{"issue":"10","key":"10.1016\/j.urolonc.2022.09.012_bib0021","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.012_bib0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.012_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.urolonc.2020.09.031","article-title":"Bacillus Calmette-Guerin (BCG): its fight against pathogens and cancer","volume":"39","author":"Sfakianos","year":"2021","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.012_bib0024","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"International Journal of Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.012_bib0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-Cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"Journal of Urology"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0026","article-title":"Mycobacterium bovis bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cells","volume":"2010","author":"Luo","year":"2010","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.012_bib0027","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy","volume":"55","author":"Ayari","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.012_bib0028","article-title":"621\u2005NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients","volume":"9","author":"Horowitz","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.012_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-\u03b3 production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.urolonc.2022.09.012_bib0030","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood.V77.9.2008.2008","article-title":"Cell-type specificity of interferon-gamma-mediated HLA class I gene transcription in human hematopoietic tumor cells","volume":"77","author":"Radford","year":"1991","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.urolonc.2022.09.012_bib0031","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2007.01.012","article-title":"The PD-1\/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma","volume":"185","author":"Cheng","year":"2007","journal-title":"J Neuroimmunol"},{"issue":"19","key":"10.1016\/j.urolonc.2022.09.012_bib0032","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.urolonc.2022.09.012_bib0033","first-page":"2625","article-title":"Interferons increase transcription of a major histocompatibility class I gene via a 5\u2032 interferon consensus sequence","volume":"7","author":"Sugita","year":"1987","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.urolonc.2022.09.012_bib0034","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1073\/pnas.84.10.3380","article-title":"Regulation of murine class I genes by interferons is controlled by regions located both 5\u2032 and 3\u2032 to the transcription initiation site","volume":"84","author":"Korber","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4845","key":"10.1016\/j.urolonc.2022.09.012_bib0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1126\/science.3125612","article-title":"Regulation of gene expression by interferons: control of H-2 promoter responses","volume":"239","author":"Korber","year":"1988","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.urolonc.2022.09.012_bib0036","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/j.1460-2075.1989.tb08356.x","article-title":"Altered regulation of MHC class I genes in different tumor cell lines is reflected by distinct sets of DNase I hypersensitive sites","volume":"8","author":"Maschek","year":"1989","journal-title":"EMBO J"},{"issue":"15","key":"10.1016\/j.urolonc.2022.09.012_bib0037","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1073\/pnas.81.15.4917","article-title":"Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts","volume":"81","author":"Collins","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.012_bib0038","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1073\/pnas.83.2.446","article-title":"Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro","volume":"83","author":"Collins","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.012_bib0039","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41592-020-01038-7","article-title":"Spatially resolved transcriptomics adds a new dimension to genomics","volume":"18","author":"Larsson","year":"2021","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.012_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27798-0","article-title":"Spatial transcriptomics using combinatorial fluorescence spectral and lifetime encoding, imaging and analysis","volume":"13","author":"Vu","year":"2022","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.012_bib0041","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"20","key":"10.1016\/j.urolonc.2022.09.012_bib0042","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","article-title":"Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer","volume":"80","author":"Bellmunt","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0043","article-title":"Somatic features of response and relapse in non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy","author":"Bacon","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.012_bib0044","article-title":"A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Gu\u00e9rin (BCG) therapy","volume":"38","author":"Steinberg","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.urolonc.2022.09.012_bib0045","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.09.012_bib0046","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0047","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000002078.08","article-title":"Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy","author":"Lotan","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0048","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","author":"Sj\u00f6dahl","year":"2021","journal-title":"European Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.012_bib0049","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"7492","key":"10.1016\/j.urolonc.2022.09.012_bib0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Cancer genome atlas research N. comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.012_bib0051","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.urolonc.2022.09.012_bib0052","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","volume":"78","author":"Robertson","year":"2020","journal-title":"Eur Urol"},{"issue":"46","key":"10.1016\/j.urolonc.2022.09.012_bib0053","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high-risk non-muscle invasive bladder cancer","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0054","doi-asserted-by":"crossref","unstructured":"de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boev\u00e9 ER, et al. Non-muscle invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin. medRxiv. 2021:2021.11.30.21266988.","DOI":"10.1101\/2021.11.30.21266988"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0055","doi-asserted-by":"crossref","unstructured":"Strandgaard T, Lindskrog SV, Nordentoft I, Christensen E, Birkenkamp-Demtr\u00f6der K, Andreasen TG, et al. Elevated T-cell exhaustion and urinary tumor DNA levels are associated with BCG failure in patients with non-muscle invasive bladder cancer. medRxiv. 2022:2022.03.23.22272806.","DOI":"10.1101\/2022.03.23.22272806"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0056","unstructured":"AstraZeneca. Assessment of efficacy and safety of durvalumab plus BCG compared to the standard therapy with BCG in non-muscle invasive bladder cancer 2022 [updated October 31. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03528694."},{"key":"10.1016\/j.urolonc.2022.09.012_bib0057","unstructured":"Merck S, Dohme C. Efficacy and safety of pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in high-risk non-muscle invasive bladder cancer (HR NMIBC) (MK-3475-676\/KEYNOTE-676) 2022 [updated December 31. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03711032."},{"key":"10.1016\/j.urolonc.2022.09.012_bib0058","unstructured":"Pfizer. Sasanlimab (PF-06801591) in combination with BCG or as single agent in participants with high-risk non-muscle invasive bladder cancer 2024 [updated June 3. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04165317."},{"key":"10.1016\/j.urolonc.2022.09.012_bib0059","unstructured":"Sidney Kimmel Comprehensive Cancer Center at Johns H. Intravesical gemcitabine and docetaxel for BCG na\u00efve non-muscle invasive bladder cancer 2022 [updated August. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04386746."},{"issue":"15","key":"10.1016\/j.urolonc.2022.09.012_bib0060","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2021.39.15_suppl.4541","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"39","author":"Black","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.urolonc.2022.09.012_bib0061","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.012_bib0062","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"Journal of Urology"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0063","unstructured":"National Cancer I. Testing the addition of an anti-cancer drug, pembrolizumab, to the usual intravesical chemotherapy treatment (Gemcitabine) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer 2022 [updated March 31. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04164082."},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.012_bib0064","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.urolonc.2022.09.012_bib0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0066","unstructured":"CG oncology presents interim phase 2 data with CG0070 in combination with KEYTRUDA\u00ae (pembrolizumab) in non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guerin [press release]. https:\/\/www.cgoncology.com\/news\/press-releases\/041322\/2022."},{"key":"10.1016\/j.urolonc.2022.09.012_bib0067","unstructured":"ImmunityBio I. QUILT-3.032: a multicenter clinical trial of intravesical Bacillus Calmette-Guerin (BCG) in combination w ith ALT-803 (N-803) in patients with BCG unresponsive high grade non-muscle invasive bladder cancer 2022 [updated January. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03022825."},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.012_bib0068","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2022.40.6_suppl.431","article-title":"Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15R\u03b1Fc superagonist N-803 (Anktiva) and BCG infusion","volume":"40","author":"Chang","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.012_bib0069","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0070","unstructured":"Janssen R, Development LLC. A study of erdafitinib versus investigator choice of intravesical chemotherapy in participants who received Bacillus Calmette-Gu\u00e9rin (BCG) and recurred with high risk non-muscle-invasive bladder cancer (NMIBC) 2022 [updated October 26. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04172675."},{"key":"10.1016\/j.urolonc.2022.09.012_bib0071","unstructured":"Janssen R, Development LLC. A study of TAR-200 in participants with muscle-invasive urothelial carcinoma of the bladder who are ineligible for or refuse cisplatin-based chemotherapy and who are unfit for radical cystectomy 2019 [updated December 23. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03404791."},{"key":"10.1016\/j.urolonc.2022.09.012_bib0072","unstructured":"Taris Biomedical LLC. Safety and tolerability of TAR-200 mg in subjects with non-muscle-invasive bladder cancer 2018 [updated January. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02720367."},{"key":"10.1016\/j.urolonc.2022.09.012_bib0073","unstructured":"Janssen R, Development LLC. A study of TAR-200 in combination with cetrelimab, TAR-200 alone, or cetrelimab alone in participants with non-muscle invasive bladder cancer (NMIBC) unresponsive to intravesical Bacillus Calmette-Guerin who are ineligible for or elected not to undergo radical cystectomy 2022 [updated October 24. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04640623."},{"issue":"7867","key":"10.1016\/j.urolonc.2022.09.012_bib0074","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2022.09.012_bib0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder cancer group consensus statement on clinical trial design for patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumiguie","year":"2021","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:09Z","timestamp":1761042429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922003404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1078143922003404"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}